China-based startup Harvest Integrated Research Organization (HiRO), an innovation global contract research organisation (CRO), has announced the successful acquisition of Courante Oncology, a US-based full-service clinical research provider specialising in oncology product development.

As a reputable boutique CRO with a strong track record of delivering high-quality, expedited clinical trials in the Asia-Pacific, HiRO's acquisition of Courante Oncology marks a significant milestone in its global expansion. This strategic move further strengthens HiRO's capabilities in managing global studies, extending its presence into the US market.

Courante Oncology brings over 25 years of invaluable experience in the drug development industry. The company's expertise spans all aspects of phase 1-3 clinical trials, ranging from initial feasibility studies and protocol development to site monitoring and closeout visits. 

The synergy between HiRO and Courante Oncology creates a powerful partnership that will deliver successful clinical trials tailored to meet the evolving needs of the industry. Both companies possess robust clinical research networks, covering the Asia-Pacific region and the US, ensuring a seamless integration of expertise and resources.

The acquisition of Courante Oncology represents a significant step forward for HiRO as it continues to solidify its position as a global CRO. With a strengthened presence in the US and expanded capabilities, HiRO is well-positioned to deliver innovative and expedited clinical trial solutions to its clients worldwide.